Pembrolizumab Treatment-Induced Liver Toxicity

to related objects

Abstract: T cells play a critical role in immune responses against neoplasm. This finding contributed to the immunotherapy development, an effective treatment for many cancers nowadays. Programmed cell death protein 1 (PD1) is an inhibitory receptor on T cells which downregulate T-cell function per ligation with its ligands (PDL1 and PDL2). PD1 blockade is used to enhance antitumor immunity. Pembrolizumab is a humanized monoclonal anti-PD1 antibody currently used in the management of melanoma, non-small-cell lung cancer, and Hodgkin lymphoma. Most of the treatment toxicities are immune-related adverse events, but grade 3–4 toxicities occur in up to 5% of patients, mainly dermatologic. We present a case of grade 4 pembrolizumab-induced liver toxicity associated with an excellent treatment response in a Caucasian woman.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Pembrolizumab Treatment-Induced Liver Toxicity ; volume:15 ; number:2 ; year:2021 ; pages:742-750 ; extent:9
Case reports in gastroenterology ; 15, Heft 2 (2021), 742-750 (gesamt 9)

Creator
Calderon, Benoît
Stancu, Alma
Vanel, François-Roger
Vazquez, Léa

DOI
10.1159/000518128
URN
urn:nbn:de:101:1-2409120017563.383672224039
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:25 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Calderon, Benoît
  • Stancu, Alma
  • Vanel, François-Roger
  • Vazquez, Léa

Other Objects (12)

Pembrolizumab Treatment-Induced Liver Toxicity

Pembrolizumab Treatment-Induced Liver Toxicity

Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy

Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report

Pembrolizumab-Induced Delayed-Onset Hepatitis

Pembrolizumab-Induced Delayed-Onset Hepatitis

Pembrolizumab-Induced Toxic Epidermal Necrolysis

Pembrolizumab-Induced Toxic Epidermal Necrolysis

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge

Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge

Pembrolizumab

Pembrolizumab

A toxicogenomic- and pharmacovigilance-based evaluation of drug-induced liver toxicity

Hochschulschrift

A toxicogenomic- and pharmacovigilance-based evaluation of drug-induced liver toxicity

Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity

Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity

Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity

Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity

Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress

Pre-administration of turmeric prevents methotrexate-induced liver toxicity and oxidative stress

Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model

Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model

Related objects